DNA damage, such as that elicited by UV-B, can induce either a cell cycle arrest or apoptosis that can be signalled by the p53 protein through the activation of a number of downstream cellular target genes. In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate proteolytic degradation of p53, the E6 protein of cutaneous HPVs, such as HPV 77, do not promote p53 degradation. We have previously shown, however, that expression of HPV 77 E6 can effectively block UV-induced apoptosis in cells that have UV-activated p53. Here, we report that expression of the E6 protein from the cutaneous HPV 77 attenuates the UV-induced transactivation of p53-regulated proapoptotic genes Fas, PUMAb, Apaf-1, PIG3. This inhibition of p53-activation of proapoptotic genes by HPV77 E6 is exerted selectively, as the increased expression of p53 target genes involved in cell cycle arrest or regulatory functions regulation, such as p21 and Hdm2, is unaffected. Our data suggest that HPV 77 E6 may play an important role in specifically deregulating p53-dependent transactivation of proapoptotic genes upon UV-B irradiation.
Ultraviolet (UV) radiation is a powerful mutagenic agent which leads to the formation of DNA photoproducts that interfere with the correct replication and transcription of the genetic material. Protection of genomic integrity is mediated through cellular responses involving the expression of different sets of genes that perform functions such as DNA repair, cell cycle arrest and the induction of apoptosis. Among such genes, a key player is the human TP53, which is the most frequently mutated gene in carcinomas, with over 50% of all human tumours harbouring a p53 mutation (Levine, 1997) . The p53 tumour suppressor protein is mantained at low intracellular levels by the action of Hdm2 that targets p53 for proteosomal degradation and is itself a p53-regulated gene (Haupt et al., 1997; Kubbutat et al., 1997) . However, following genotoxic stress and oncogenic stimuli, a number of post-translational modifications occur on the p53 protein leading to its stabilization and activation (Appella and Anderson, 2001; Pluquet and Hainaut, 2001; Vousden, 2002) . Upon activation, the p53 protein is able to transactivate a number of downstream genes, some of which have been shown to be involved in cell cycle arrest and apoptosis (Polyak et al., 1997; Oda et al., 2000; Nakano and Vousden, 2001; Yu et al., 2001) . At present how these complex series of post-translational modifications modulate p53-induced responses, including cell cycle arrest and apoptosis, is still a subject of intense study.
The modulation of p53-dependent responses may also be influenced by the interaction of p53 with transcriptional coactivators, such as CREB and p300 (Scolnick et al., 1997) . Binding of the p53 protein to members of the Aspp family selectively favours the transcriptional activation of proapototic p53 target genes, thus resulting in a potentiated apoptotic response (Samuels-Lev et al., 2001) . These data raise the possibility that different p53 activities could be modulated by either mutation in p53 itself or binding to other proteins, and that impairment of such interactions may be important in carcinogenesis.
Inactivation of p53-induced responses is a common event in tumour progression, as most p53 mutants have lost their DNA binding and transactivation capabilities. However, some p53 mutants retain transcriptional activation capabilities towards the p21 promoter but not towards proapoptotic targets genes such as Bax and these mutants thus show reduced apoptotic function Campomenosi et al., 2001) .
Many DNA tumour viruses, including adenonviruses and Epstein-Barr virus, have evolved strategies aimed at eluding the p53 surveillance (Wattre et al., 1996) . Among such viruses are also the anogenital HPVs that have been associated with cervical tumour development. The 'high-risk' types, such as HPV16 and HPV18, express the oncogenic E6 protein which is able to target p53 for ubiquitin-mediated proteosomal degradation (Mantovani and Banks, 2001) .
In addition to anogenital cancers, HPVs have been also implicated in the development of UV-B-induced squamous cell carcinomas (SCCs) of the skin. Patients affected by the rare inherited disorder Epidermodysplasia Verruciformis (EV) and renal transplant recipients (RTRs) develop a large number of flat warts, a significant proportion of which undergo malignant transformation at sun-exposed sites. HPV warts and skin cancers tend to colocalize, thereby suggesting that the tumours arise from the viral warts. Studies have shown that 90% of tumours in EV patients show the presence of HPVs, particularly types 5 and 8, which are commonly referred to as EV-associated types (Orth, 1986) . RTR patients are instead subject to mixed infection with many different cutaneous types, including the recently isolated type HPV 77 (Delius et al., 1998; Surentheran et al., 1998; de Villiers et al., 1999; Harwood et al., 2000) . It is important to note that although the EV types are included in the cutaneous group, they are distant phylogenetically from other cutaneous types and it has recently been argued that they may define a distinct subgroup within the cutaneous branch (Orth et al., 2001) .
In contrast to anogenital HPV types, the E6 protein of HPV types 5 and 8 lack the ability to promote p53 degradation (Steger and Pfister, 1992; . Previously we have shown that UVinduced apoptosis is abrogated in p53 wild-type cells that express the E6 protein from diverse cutaneous HPV types, including HPV77 . This inhibition of apoptosis is partly due to targeting of the proapoptotic protein Bak for proteolysis, an activity shared by the E6 proteins of all cutaneous HPV types so far analysed . However, the fact that expression of the E6 protein of cutaneous HPV 5 and HPV 77 types is still capable of inhibiting UVinduced apoptosis under conditions that lead to p53 activation suggest that the viral proteins may specifically interfere with p53-mediated apoptotic pathways. This antiapoptotic activity of cutaneous HPVs has been postulated to be a general mechanism by which a broad spectrum of diverse HPV types may contribute towards tumour development (Storey, 2002) .
We therefore investigated whether specific p53-induced responses were compromised in UV-B-irradiated cells expressing the E6 proteins from HPV 5 and HPV 77. Previous data showing that the cutaneous E6 proteins inhibited UV-induced apoptosis in the presence of activated p53 suggested that either the E6 proteins targeted downstream apoptotic effectors, or that the activity of p53 itself was modulated. To address the question whether UV-induced p53-dependent responses were compromised by expression of different HPV E6 proteins, we analysed the expression pattern of p53-regulated genes and proteins in E6-expressing cell lines after UV irradiation.
For these experiments, HT1080 cells, which express both the codon 72 arginine and proline (arg/pro) isoforms of wild-type p53, were transfected with the pcDNA3 plasmid constructs expressing either the HPV 5, 18 or 77 E6 genes. In all transfection experiments, the proline form of p53 was used except where indicated specifically. As a control, cells were also transfected with the pcDNA3 plasmid alone. Following selection in media containing 500 mg/ml G418, polyclonal cell lines bearing the E6 or vector control were generated and expression of the relevant E6 gene was confirmed by RT-PCR (data not shown). DNA sequencing confirmed that the transfected cells had not acquired mutations in the p53 gene during the selection with G418. Since longterm passaging of cells expressing E6 promotes genetic instability and is therefore likely facilitate the accumulation of mutations, the polyclonal lines were expanded to near confluence in T175 cm 2 flasks and then divided into aliquots for freezing. For each experiment, a fresh vial of frozen cells was recovered, passages once and any remaining unused cells were discarded. Cells of each line were plated and either left unirradiated, or a p53 response was induced by exposure to a single dose of 15 mJ/cm 2 of UV-B, and harvested 24 h later. The induction of p53 and of p53-regulated genes was then investigated by performing Western blot analysis on cell extracts ( Figure 1a ). p53 target genes involved in both cell cycle arrest, such as p21, and apoptosis, such as PIG3 (involved in ROS-mediated apoptosis) and Fas (involved in receptor-mediated apoptosis) were investigated as markers of p53 activation.
The p53 protein was potently induced in control, HPV5 E6 and HPV77 E6 cells after UV-B irradiation. As expected, only residual levels of p53 protein were observed in irradiated cells expressing HPV18 E6, which promotes p53 degradation. Upon irradiation, the cell cycle inhibitor p21 reached similar levels in control, HPV5 E6 and HPV 77 E6 cells, while it was not induced in HPV18 E6 cells, in agreement with our previous observations . Cells transfected with the control plasmid or HPV5 E6 displayed a marked increase in the levels of Fas and PIG3 proteins after irradiation, reaching levels of expression similar to those observed in irradiated control cells. However, this marked increase was not observed in irradiated cells expressing HPV18 or HPV 77 E6 (Figure 1a ). Although the different E6 proteins are expressed from the same vector and selected with the same concentration of G418, it is possible that this differential expression of p21 and PIG3 in the cells expressing the different E6 proteins may be due to different levels of E6 protein expression. To test this possibility, we performed expression studies on HA-tagged E6 proteins. Oligos encoding the HA tag were inserted between the HindIII and BamHI sites of the pcDNA3 vector used to construct the polyclonal E6 cell lines above. The different E6 genes were then amplified by PCR cloned between the BamHI and XhoI sites to generate proteins with an HA tag at the N-terminus of the protein. The plasmids encoding the E6-tagged genes were transfected into HT1080 cells and selected with G418 to generate polyclonal lines. Western blotting of cell extracts showed that the levels of the different E6 proteins were equivalent in each of the cell lines ( Figure 1b) . Thus, the differences in expression of Fas and PIG3 proteins was not attributable to different levels of E6 expression, but was more likely due to inherent differences in the activities of the different E6 proteins.
As p53 was still induced in the HPV 77 E6 cell lines, we speculated that transcriptional activation of proapototic promoters might be compromised following irradiation in these cells. To test this hypothesis, we Deregulation of transactivation proapoptotic genes by HPV 77 E6 S Giampieri et al performed a reporter gene assay for p21 and PIG3 promoters in control and E6-expressing cell lines after irradiation ( Figure 2 ). As expected, in cells expressing the HPV18E6, no increase in the transcription from either promoter was observed upon UV-B irradiation. Transcriptional activation from both p21 and PIG3 promoters was increased to similar levels after irradiation in cells expressing either the control plasmid or HPV5E6, consistent with the protein expression data shown in Figure 1a . In HPV 77 E6-expressing cells, transcription from the p21promoter was activated upon UV-B stimulation and reached the same levels observed in control cells. Notably however, transcriptional activation of PIG3 promoter appeared compromised and failed to reach levels observed in the control cells. Overall, this data indicate that HPV 77 E6 selectively reduced the ability of p53 to activate PIG3 promoter and this was responsible for the lower PIG3 protein levels observed in cells expressing HPV 77 E6.
As UV-B is able to activate the expression of a number of genes in addition to p53 (Sesto et al., 2002) , we then tested whether the downstream p53 responses observed were directly due to p53-dependent regulation by performing Western blots and reporter gene assays in p53-null cells. For these experiments, we used the p53-null cell line RTS3b (Rapp et al., 1997) , which is a spontaneously immortalized line derived from cutaneous epithelium, the natural host cells for cutaneous HPVs in vivo. RTS3b cells were transfected with the control plasmid either singularly or in combination with p53 and the HPV E6 expressing plasmids. Results from Western blot analysis on cell extracts are shown in Figure 3 . As expected, cells transfected with the control plasmid do not express p53, p21 or PIG3 proteins. Transfection of p53 results in powerful expression of p53 and also the p21 and PIG3 proteins. In cells cotransfected with p53 and HPV 5 E6, levels of p53, p21 and PIG3 proteins were similar to those observed in p53-transfected cells, while expression of HPV18 E6 causes degradation of the p53 protein and blocks expression of p21 and PIG3 proteins. Cells transfected with p53 and HPV 77 E6 displayed levels of expression of p53 and p21 proteins comparable to those observed in cells transfected with p53 alone. However, PIG3 protein expression was not observed, indicating that the effect of ) were plated on 100 mm dishes, irradiated and protein extracted 24 h later. Prior to harvesting, the cells were washed twice with PBS, then incubated with 300 ml of lysis buffer (50 mM HEPES, 250 mM NaCl, 0.1% Nonidet-P40 and 1 Â cocktail inhibitors (Boehringer Mannheim)). The remaining cellular debris and membrane fractions were pelleted by centrifugation at 13000 r.p.m. in a microcentrifuge and half of the supernatant was collected. The protein concentration of the supernatant, containing cytoplasmic and nuclear proteins, was determined using BioRad protein assay reagent. After adding an equal volume of 2 Â Laemmli buffer and boiling for 5 min, equal amounts of proteins were separated by SDS-PAGE and transferred to a polyvinylidienefluoride (PDVF) membrane. p53, p21, PIG3 and a-tubulin (loading control) were detected on this membrane (upper panel). The cellular debris and membranes containing fraction, which also contains Fas, was mixed with an equal volume of 2 Â Laemmli buffer, boiled for 5 min and equal volumes loaded on a separate gel (lower panel). The blots were probed with specific antibodies: p53 (DO1, Cancer Research UK laboratories), p21 (sc-187, Santa Cruz Biotechnology), PIG3 (OP148, Oncogene Research Products), Fas (sc-714-R, Santa Cruz Biotechnology) and a-tubulin (CP06, Oncogene Reaserch Products). The signal was developed using the ECL þ kit (Amersham). (b) Expression of HA-tagged E6 proteins. The HA epitope tag was inserted into the pcDNA3 expression vector between the HindIII and BamHI sites using the following primer pair: HA-F AGCTTACCATGGCCTACCCCTACGACGTGCCCGACTACGCCTCCCTCG; HA-R GATCCGAGG GAGGCGTAGTCGGGCACGTCGTAGGGGTAGGCCATGGTA. HPV E6 sequences were amplified by PCR (2 mM MgCl 2 , 200 mM each dNTP, 2 U PFU polymerase, 25 ng of E6 template, 200 ng oligos) with the following cycling programme: 5 Â (951C/1 min 551C/30 s 721C/1 min), 30 Â (951C/1 min 651C/3 s 721C/1 min), 721C/10 min, using the following primer pairs (the initiation ATG codon of the E6 genes was omitted in each case): 18E6F GCGCGGATCCGCGCGCTTTGAAGATCCAACACG (the underlined A was used in place of the wild-type G base to avoid the creation of a BamHI site without altering the coding sequence); 18E6R GCGCCTCGAGTTATACTTGTGTTTCTCTG; 5E6F GCGCGGATCCGCTGAGGGAGCCGAACAC; 5E6R GCGCCTCGAGTTACCAATCATGATAAAAATGC; 77E6F GCGCGGATCCTC TACAAGTGATGGACGT; 77E6R GCGCCTCGAGTTACTGTCGGCTTTGGCCC. The amplified product was inserted into the BamHI and XhoI sites of the HA-pcDNA3 vector and DNA sequenced. Recombinant plasmids (10 mg) were transfected into 1.5 Â 10 6 cells HT1080 cells in a 90 mm culture dish and selected with 500 mg/ml G418. Cell extracts were prepared from 2 Â 10 6 cells lysed in 100 ml 7 M urea, 2 M thiourea, 2% CHAPS, 40 mM Tris HCl pH 7.5, 0.25% glycerol, 1 mM DTT, 1 Â Protease cocktail inhibitors (Boehringer) for 10 min on at 41C. Cellular DNA was fragmented by sonication. A measure of 15 ml of extract was then subjected to SDS-PAGE and Western blotted, HA tagged proteins were detected using the anti-HA monoclonal antibody 16B12 (Covance, CA, USA)
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S Giampieri et al 77 E6 on p53 target genes following UV treatment was due to compromised p53 function. To test whether the lack of PIG3 expression following transfection of p53 and HPV 77 E6 into RTS3b cells was mediated at the transcriptional level, we performed reporter gene assays. RTS3b cells were transfected with luciferase reporter plasmids for either the p21 or PIG3 genes either singularly or in combination with p53 and the HPV E6-expressing plasmids (Figure 4a) . These experiments showed that transfection of RTS3b cells with PIG3 and p21 promoters together with any of the E6-expressing plasmid did not elicit transactivation, the levels of promoter activity being very similar to those observed in cells transfected with the promoter alone. In contrast, cotransfection of the PIG3 or p21 promoter with p53 resulted in a dramatic increase in the reporter gene transcription. In cells transfected with p53 and HPV 18 E6 transcriptional activation from both promoters was severely impaired, as expected. Marked differences between the activities of HPV 5 and HPV 77 E6 were however observed. In cells transfected with p53 and HPV 5 E6, transcriptional activation from both p21 and PIG3 promoter reached levels similar to those observed in cells transfected solely with p53, indicating that HPV 5E6 expression does not interfere with p53-mediated transactivation of these promoters. Cotransfection of HPV 77 E6 with p53 did not interfere with the p53-mediated transcriptional activation of the p21 promoter, the activity of which was comparable to those observed in cells transfected only with p53. In contrast, transfection of HPV 77 E6 impaired p53-mediated transcriptional activation of the PIG3 promoter and levels of activation were inferior to those observed in cells transfected with p53 alone. Transfecting increasing amounts of the HPV 77 E6-expressing plasmid caused a further decrease in the levels of PIG3 promoter activation, suggesting that HPV 77 E6 affected p53-dependent transcription from this promoter in a dose-dependent manner. Taken together, Figures 3 and 4a indicate that p53-mediated transcriptional activation of the PIG3 promoter is significantly reduced by expression of HPV 77 E6 and that such impairment results in a concomitant loss of PIG3 protein expression.
We have previously shown that the two common polymorphic isoforms of wild-type p53, the codon 72 arg/pro variants, have differential susceptibility to degradation promoted by oncogenic HPV types, including HPV18. As noted above, the HT1080 cells used in our initial experiments express both arg and pro forms of p53. To test whether the different p53 protein isoforms differentially affected activation of gene transcription, we performed transient reporter assays using the arg and pro forms in RTS3b cells. No significant differences in the ability of the two p53 arg and pro protein isoforms to activate either the p21 or PIG3 reporter constructs was observed, indicating that this polymorphism is not implicated in the selective inhibition of gene activation by HPV77 E6 (Figure 4b) .
Having confirmed the ability of HPV 77 E6 to interfere with p53-mediated transactivation of PIG3 Figure 3 Western blot analysis of p53, p21and PIG3 protein levels in RTS3b cells. a-tubulin was included as loading control. Cells (5 Â 10 5 ) were plated on 100 mm dishes, transfected with the indicated amounts of either control, p53 or p53 and E6-expressing plasmids. Cells were collected 24 h post transfection and the cell extract was obtained as described before. Equal amounts of total protein were loaded onto SDS-PAGE gel, transferred to PVDF membrane and incubated with specific antibodies. Signal detection was performed as described above Figure 2 PIG3 and p21 promoter activation in HT1080 cell lines after UV irradiation. The graphs represent the average of three independent experiments, while the error bars represent the standard deviation. Cells were transfected with 2 mg of either PIG3 (a) or p21 (b) promoter using calcium phosphate method. At 8 h post transfection, cells were irradiated at 15mJ/cm 2 and collected 16 h afterwards. Cells were washed twice with PBS and then lysed with 150 ml of 1Â cell culture lysis reagent (CCLR, Promega). The lysate was cleared of any debris by centrifugation in a microfuge at 13000 r.p.m. for 3 min. Then, 10 ml of lysate were added to 10 ml of 1 Â CCLR and 100 ml of reconstituted luciferase assay reagent (LAR, Promega). Luminescence was measured by using Wallac 1400 lunimometer Deregulation of transactivation proapoptotic genes by HPV 77 E6 S Giampieri et al promoter, we next investigated whether this mechanism could be extended to include other p53-regulated proapoptotic genes. To investigate this possibility, we compared the levels of activation of p53-induced genes involved in apoptosis to other p53 targets involved in cell cycle arrest or other regulatory functions. As before, HT1080 cells expressing the E6 genes were plated and either left unirradiated or exposed to a single dose of 15 mJ/cm 2 UV-B and harvested at various time points. RNA was then extracted and RT-PCR was performed for a variety of proapoptotic and cell cycle/regulatory p53-induced genes. These included PIG3, Apaf-1, Pumab Fas, p21, Gadd45, 14-3-3s and Hdm2 (Figure 5 ). Upon UV-B irradiation, a significant increase in the levels of transcripts of all the above p53-induced genes was observed in control cells. As expected, little or no increase in mRNA levels for any of the p53 target genes was observed in irradiated HPV18E6 cells, a pattern consistent with p53 degradation. In cells expressing HPV5 E6, the increase in the levels of transcripts of p53-induced genes was similar to that observed in the irradiated control cells. In contrast, the pattern of activation of some p53-induced genes appeared altered in cells expressing HPV 77 E6. In particular, after irradiation little or no increase was observed in the levels of transcripts of proapoptotic genes, while levels of transcripts of genes involved in cell cycle arrest or regulatory function were similar to those observed in the irradiated control cells. This apparent dichotomy in the regulation of proapototic versus cell cycle/regulatory p53-induced genes resembled that observed for previously described p53 mutants Rowan et al., 1996; Campomenosi et al., 2001) .
Overall, our observations suggest that different mechanisms are be used by different HPVs in order to avert p53-induced apoptosis in UV-irradiated cells. While degradation of the p53 protein is observed in HPV 18 E6 cells, no such degradation could be observed in any of the cutaneous E6-expressing cells. In HPV5 E6-expressing cells p53 and p53-dependent activities appear unaffected, suggesting that the mechanism by which p53-induced apoptosis is relieved may lie in events downstream of p53 activation. In agreement with our previous studies, the HPV5 or HPV77 E6 proteins were unable to inhibit the accumulation of p21 following UV damage and interestingly, we have not observed an UV-induced growth arrest in HT1080 cells expressing HPV5 or HPV77 E6 . These results suggest that either the p21 protein may not be active in these cells, perhaps as a result of cellular mislocalization, or that another as yet undefined E6 activity is responsible for over-riding a p21-mediated cell cycle arrest. Supporting the latter idea is evidence that the HPV18 E6 protein has an undefined activity that regulates the progression through G1 (Storey et al., 1995) , and the HPV16 E6 protein can drive cells overexpressing p16 INK4A or p27 KIP1 into S phase (Malanchi et al., 2002) . However, the exact mechanism utilized by the cutaneous HPV E6 proteins to overcome p21 cell cycle arrest remains to be determined.
Our data ascribe a novel activity to the HPV 77 E6 protein, whose expression effectively targets p53-dependent apoptosis while not interfering with p53-mediated cell cycle arrest. We show that this is due to the selective impairment of p53-regulated transcription of proapoptotic genes, while p53-dependent expression of cell cycle or regulatory genes is not affected. As HPV 77 is found in tumours of immunocompromised patients, this activity of HPV 77 could, at least in part, explain how p53-induced apoptosis at sun-exposed sites may be averted in absence of p53 degradation. We previously reported that the HPV 77 URR (upstream regulatory region), which controls the expression of the E6 and E7 genes, contains a p53-responsive element and can be transcriptionally activated by p53 (Purdie et al., 1999) . Therefore in HPV 77 cells, resistance to apoptosis could facilitate proliferation of infected cells and further the tumorigenic process by increasing the expression of E6 or other viral proteins.
At present, the mechanism by which the HPV 77 E6 affects expression of p53-induced proapoptotic genes is unclear. One possibility is that HPV 77 E6 is able to interfere with the occupancy of selected promoters by p53, possibly by binding to protein and changing its affinity for such promoters. Alternatively, it is possible that HPV 77 E6 is able to modulate events leading to p53 activation, such as phosphorylations and acetylations, that are essential to its functional activity (Appella and Anderson, 2001; Pluquet and Hainaut, 2001; Vousden, 2002) . Currently, HPV 77 is the only viral type we have found capable of discriminating between p53-activated genes; however, it would be interesting to ascertain whether other cutaneous types also share this activity. HPV5, which is also a cutaneous type, belongs to EV-associated subgroup that is phylogenetically distinct from that of HPV 77. As HPV 5 E6 expression does not interfere with p53-dependent gene expression, it is possible that this mechanism may not apply to EV cutaneous types in general. Interestingly however, this novel activity of HPV 77 E6 further highlights the complexity of the control of p53 activity and responses and in addition suggests that there may be additional routes by which p53 activation can be modulated. Figure 5 UV-induced expression of p53-regulated proapoptotic, cell cycle and regulatory genes. Cell lines were created by calcium phosphate-mediated transfection of pcDNA (vector control) or pcDNA:E6 plasmids into HT1080 cells (WT p53). Transformants were selected in DMEM medium containing 10% serum supplemented with 500 mg/ml G418. Equal expression of the E6 genes was verified by RT-PCR (data not shown). Cells (5 Â 10 5 ) from each line were plated, UV irradiated at 15 mJ/cm 2 and collected at different time points. Nonirradiated controls (0) are also included. RNA was extracted using RNazol B (Biogenesis) and reverse transcription was performed using the GeneAmp RNA PCR Kit (Perkin-Elmer). Finally, PCR was performed on total cDNA, using primers specific for each gene of interest. Primers used: PIG3 F ATGTCAGAACCGGCTGGGGAT; PIG3 R TGTTCTTGTTG GCCTCCATGT; p21 F ATGTCAGAACCGGCTGGGGAT; p21 R GGGCTTCCTCTTGGAGAAGAT; HDM2 F TGTCTGTACT GATGGTGC; HDM2 R CACTCCCACCTTCAAGGTGAC; Fas F GGACCCTCCTACCTCTGGTTCT; Fas R CTGGGTCCGG GTGCAGTTTA; 14-3-3s F GAAAAGCAACGAGGAGGGGC TCGG; 14-3-3s R TGTCGGCCGTCCACAAGTGTC; GADD45 F GAGCTGCCGGAGCGGCGCCT; GADD45 R TTGAGCAGC TTGGCCGCTTG; Apaf1 F GGGACT CTTGGGTGTTGAAA; Apaf1 R CTGGCAAATCTGCCTTCTTC; PUMAb F GGAT GAAATTTG GCATGGGGTCT; PUMAb R GGACAAGTCAG GACTTGCAG; G6PDH F GTTCCGTGAGGACCAGATCTAC; G6PDH R GGCTCCTTGGAAGGTGAGGATAA. After an initial step of 5 min at 951C, for each primers set, we performed 25 cycles of amplification as follows; denaturation at 951C for 30 s, annealing at 551C for 45 s, extension at 721C for 30 s. A final step at 721C was then performed for 10 min. Annealing temperatures differ for the 14-3-3 s primer set (601C) and GADD45 primers set (661C)
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